Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy

Anaplastic lymphoma kinase (ALK) inhibitors have been successfully developed for non-small cell lung carcinoma (NSCLC) displaying chromosomal rearrangements of the ALK gene, but unfortunately resistance invariably occurs. Blockade of the PD-1-PD-L1/2 inhibitory pathway constitutes a breakthrough for...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Hélène Roussel, Eléonore De Guillebon, Lucie Biard, Marion Mandavit, Laure Gibault, Elisabeth Fabre, Martine Antoine, Paul Hofman, Michèle Beau-Faller, Hélène Blons, Claire Danel, Françoise Le Pimpec Barthes, Alain Gey, Clémence Granier, Marie Wislez, Pierre Laurent-Puig, Stéphane Oudard, Patrick Bruneval, Cécile Badoual, Jacques Cadranel, Eric Tartour
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Taylor & Francis Group 2017-04-01
Saila:OncoImmunology
Gaiak:
alk-positive adenocarcinoma
immunotherapy
in situ quantitative cell imaging
predictive biomarker
tumor microenvironment
Sarrera elektronikoa:http://dx.doi.org/10.1080/2162402X.2017.1286437
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak